Viewing Study NCT00131833



Ignite Creation Date: 2024-05-05 @ 11:47 AM
Last Modification Date: 2024-10-26 @ 9:13 AM
Study NCT ID: NCT00131833
Status: COMPLETED
Last Update Posted: 2008-03-13
First Post: 2005-08-18

Brief Title: Typhoid Vi Vaccine Effectiveness in Hechi Guangxi China
Sponsor: International Vaccine Institute
Organization: International Vaccine Institute

Study Overview

Official Title: Typhoid Vi Vaccine Effectiveness in a Population Older Than 5 Years of Age Living in an Endemic Area in Hechi Guangxi PR China A Group-Randomized Controlled Demonstration Project
Status: COMPLETED
Status Verified Date: 2008-03
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: This study is part of International Vaccine Institute IVIs typhoid Vi demonstration project that aims to accelerate the rational introduction of Vi vaccines in typhoid endemic countries The purpose of this study is to determine the effectiveness of the Vi vaccine following a mass typhoid immunization campaign in an endemic area in Hechi City in the Guangxhi province of China The cost-effectiveness and safety of Vi vaccination will also be evaluated
Detailed Description: Typhoid fever is a major cause of morbidity worldwide The disease predominantly affects school-aged children is more prevalent in urban areas may last for several weeks and can lead to serious complications Management of this disease is further complicated by the emergence of multi-drug resistant strains Vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever The Vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons it has been shown to have consistent efficacy results even in areas of high typhoid incidence is given as a single dose lacks patent protection and requires less strict cold chain requirements

This project attempts to evaluate a new vaccination strategy for residents of endemic areas A cluster-randomized trial involving the Vi polysaccharide vaccine and an active control meningococcal A vaccine was designed to determine the effectiveness and the feasibility of providing Vi vaccine under actual programmatic conditions in 2 populous townships of Hechi City The vaccines used in this study are locally produced and licensed in China A 1 year pilot phase will precede the actual Vi-demonstration project Surveillance for typhoid fever cases will continue after the mass immunization campaign A passive surveillance system to evaluate adverse events following immunization will be implemented Socio-economic studies will be conducted in parallel to the effectiveness evaluation The knowledge attitudes beliefs and practices among parents and health care providers regarding typhoid illness treatment and prevention will be assessed Logistic feasibility and vaccine costs will also be determined

Secondary objectives of this trial are

To estimate the logistic feasibility of a mass typhoid immunization campaign
To assess the knowledge attitudes beliefs and practices among parents and health care providers regarding typhoid illness treatment and prevention
To study typhoid fever risk factors in the population

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None